 Mepolizumab is an anti-IL5 Interleukin 5 monoclonal antibody which blocks the eosinophilic activation pathways associated with decreasing asthma control. The pre-licensing studies have shown that Mepolizumab decreases asthma exacerbation events by approximately 50, this study seeks to understand the underlying mechanisms of the remaining 50 of exacerbations. 